A three-year-old boy presented to the endocrinology clinic at the Children's Hospital of Western Ontario (London, Ontario) with an eight-month history of progressive polydipsia and polyuria. His symptoms became obvious to his family during a recent summer vacation at Disney World (Orlando, USA), where he drank 6 L of water per day and voided every 20 min. He frequently woke up overnight to ask for water and soaked multiple diapers. There was no history of headache, fever, weight loss, fatigue, fractures or extremity pain.
A three-year-old boy presented to the endocrinology clinic at the Children's Hospital of Western Ontario (London, Ontario) with an eight-month history of progressive polydipsia and polyuria. His symptoms became obvious to his family during a recent summer vacation at Disney World (Orlando, USA), where he drank 6 L of water per day and voided every 20 min. He frequently woke up overnight to ask for water and soaked multiple diapers. There was no history of headache, fever, weight loss, fatigue, fractures or extremity pain.
He had a history of seborrheic scalp dermatitis since birth, which was unresponsive to treatment with topical steroids. He also had recurrent otitis media requiring myringotomy tubes, and recurrent otitis externa. His family history was unremarkable.
On physical examination, his height and weight were measured at the 40th and 5th percentiles, respectively. His vital signs were normal. His head and neck examinations revealed multiple discrete, superficial, yellow scaly lesions with surrounding erythema on his scalp and left-sided ptosis; fundoscopy was normal. There was mild, shotty lymphadenopathy of the cervical and inguinal regions with no associated hepatosplenomegaly.
Before his referral to the clinic, the patient had blood work on several occasions revealing normal blood glucose levels. His urinalysis, serum electrolytes and complete blood count were also normal. Further testing revealed the diagnosis.
Case 2: Seizures as a clue to…
A four-month-old girl with a history of right leg hemihypertrophy and hypopigmented skin patches presented to the emergency room with irritability and a four-day history of jerky movements. These were described as symmetrical flexion of both upper extremities, occurring in clusters lasting 5 min to 10 min.
She was afebrile with stable vital signs and no obvious dysmorphic features. Her weight was 6.7 kg (75th percentile). Several white spots were noted on her right cheek and both legs. She had right thigh hemihypertrophy. There was mildly decreased central tone with head lag and normal peripheral tone. There were no abdominal masses.
She was born to a 33-year-old G3P1A1 mother at 40 weeks' gestation by vaginal delivery. Her birth weight was 3.46 kg (between the 50th and 75th percentiles). The pregnancy was uncomplicated and her prenatal ultrasound was normal. On the first day of life, she was noted to have right leg hemihypertrophy and was seen by the genetics department. Her family history was negative for overgrowth syndromes. Her mother had one hypopigmented skin lesion on her left leg. There was no consanguinity.
Her hemoglobin, blood gas and glucose levels were normal. Her calcium level was mildly elevated at 2.95 mmol/L (normal 2.17 mmol/L to 2.44 mmol/L). The remainder of her electrolyte levels, including phosphate and magnesium, were normal. Further investigations revealed her diagnosis.
CASE 1 DIAGNOSIS: LANGERHANS CELL HISTIOCYTOSIS
Central diabetes insipidus (DI) was confirmed by a water deprivation test with vasopressin. A skeletal survey revealed lytic lesions in the left anterior frontal bone and orbital roof (Figure 1 ). On magnetic resonance imaging of the head, these lesions displayed features characteristic of eosinophilic granulomas. There was diffuse thickening of the pituitary stalk; the physiological hyperintense signal in the posterior pituitary was absent. Biopsy of the patient's scalp lesions confirmed the diagnosis of Langerhans cell histiocytosis (LCH).
The patient was started on desamino d-arginine vasopressin (DDAVP) with near complete resolution of his urinary symptoms. He underwent chemotherapy, resulting in resolution of his dermatitis, bony lesions and recurrent ear infections. There has been no evidence of other pituitary dysfunction.
Clinicians are generally quick to think of diabetes mellitus when a patient presents with polydipsia and polyuria, but it is crucial to consider other causes (Table 1) . Primary polydipsia may occur in children with compulsive or habitual excessive water intake. Psychiatric and hypothalamic causes of intense thirst are less common. Most cases of DI are acquired and other, sometimes subtle, clinical features may suggest the underlying diagnosis, as in our case. More importantly, DI should be considered even when electrolyte levels are normal because children with an intact thirst mechanism and free access to fluids can consume enough water to prevent hypernatremia.
A water deprivation test is required to differentiate between central and nephrogenic DI. However, the community paediatrician should look for associated features to direct a referral to the appropriate specialist. For example, a history of hypercalcemia, chronic renal disease, obstructive uropathy or use of medications such as lithium suggests nephrogenic DI. This would prompt referral to a paediatric nephrologist. A positive family history may point to a genetic cause of central or nephrogenic DI. Trauma related to neurosurgery or accidental brain injury can cause central DI. Signs and symptoms of increased intracranial pressure are consistent with primary brain tumours that cause central DI. Tumours located near the base of the hypothalamus may be associated with clinical evidence of other pituitary hormone dysfunction. Central DI may rarely occur in viral encephalitis, bacterial meningitis, congenital cytomegalovirus and toxoplasma infections. Approximately 10% of cases are thought to be idiopathic. LCH is a rare infiltrative disorder with diverse clinical manifestations that simulate other common conditions. The unifying feature of the disorder is the presence on histology of Langerhans cells, which normally function as antigenpresenting cells in the immune system. In LCH, abnormal immature Langerhans cells can accumulate in multiple organ systems, making the diagnosis very challenging. The most common initial presentations in children include lesions of the skin, isolated or multifocal bone lesions, lymphadenopathy and generalized symptoms such as fever and weight loss. LCH typically presents in childhood with a peak onset between one and four years of age. Incidence is approximately two to five in one million children.
The dermatological manifestations of LCH often mimic seborrheic dermatitis of infancy. Children tend to present with erythema and scaling, particularly of the scalp and groin. The presence of petechial hemorrhages within the lesions is highly suggestive of LCH, and erosive intertrigo may be seen in the groin and axillae. A variety of other skin lesions have been described, including eczematous-like rashes. Given the difficulty in distinguishing LCH from other benign dermatoses, it is important to maintain a high index of suspicion for any dermatitis that does not respond to standard therapy.
The clinical hallmark of LCH is the presence of lytic bone lesions. These eosinophilic granulomas may be identified incidentally on imaging or may present with bony pain, swelling or functional limitations. LCH can affect any bone; however, the skull, mandible, spine and ribs are most commonly involved. Lesions of the skull are typically round and osteolytic with a 'punched-out' appearance, as in our patient. Lesions of the mandible and maxilla may lead to gingival swelling and loosened teeth. Involvement of the inner ear bones may cause recurrent otitis media and mastoiditis.
Patients presenting with skull lesions are at higher risk of central nervous system involvement such as DI, which develops in over 10% of patients. Typical features on magnetic resonance imaging include thickening of the pituitary stalk with prominent contrast enhancement and loss of the normal hyperintense signal in the posterior pituitary. Other endocrine abnormalities, such as growth hormone deficiency, may arise later on.
Baseline investigations in a patient with suspected LCH include a complete blood count, electrolytes, liver function tests, urinalysis and a skeletal survey. Further investigations will depend on the presenting features of LCH. Treatment ranges from resection of local lesions to chemotherapy, and is determined by the sites of disease, degree of organ involvement and age at diagnosis, all of which are also important prognostic factors. All children with suspected or confirmed LCH should be referred to a paediatric oncologist. The outcome of LCH varies, but recurrence is common, particularly for patients like ours with multisystem disease.
CLINICAL PEARLS
• Although diabetes mellitus is a common cause of polyuria and polydipsia, it is equally important to consider other diagnoses, including DI.
• A normal electrolyte profile does not rule out a diagnosis of central or nephrogenic DI.
• LCH can mimic common childhood diseases including diaper rash, seborrheic dermatitis and recurrent otitis media. When a common condition is recalcitrant or persists beyond the expected age, this may suggest a misdiagnosis and prompt consideration of alternative explanations, such as LCH. 
CASE 2 DIAGNOSIS: TUBEROUS SCLEROSIS COMPLEX
The initial electroencephalogram showed hypsarrhythmia consistent with infantile spasms, and vigabatrin was initiated. Infantile spasms, in the context of hemihypertrophy and skin hypopigmentation, prompted a targeted evaluation for tuberous sclerosis complex (TSC).
A head ultrasound showed a focal area of hypoechogenicity in the anterior basal ganglia. Magnetic resonance imaging showed multiple cortical and subcortical tubers, and enhancing subependymal nodules adjacent to the foramen of Monro. Slit lamp examination showed a disc-size (1.8 mm) round lesion on the left eye consistent with a hamartoma. Six hypopigmented lesions were identified on Wood's lamp examination of the skin. No fibrous tumours or angiofibromata were seen. An echocardiogram was positive for four tumours in both ventricles, with no outflow tract obstructions noted. An abdominal ultrasound revealed multiple renal cortical cysts, but there was no evidence of angiomyolipoma.
Endocrine workup for hypercalcemia included adrenocorticotropic hormone (ACTH) stimulation, 1,25 dihydroxy vitamin D, cortisol, parathyroid hormone and urine osmolality, all within normal limits. The cause of the hypercalcemia was not determined, and it resolved over time with no therapy. Genetic workup was positive for female karyotype (46 XX), Beckwith-Wiedemann syndrome (methylation defect at the KvDMR1 locus) and TSC (TSC2 gene mutation).
TSC is an autosomal dominant neurocutaneous disorder characterized pathologically by the presence of hamartomas in multiple organs. Historically, TSC was defined by the triad of mental retardation, epilepsy and facial angiofibromas, although now the disorder is known to exhibit a wide variability in clinical expression. Although TSC has a known genetic basis with autosomal dominant inheritance, two-thirds of cases are the result of new mutations in one of two known tumour suppressor genes, TSC1 (encoding hamartin) and TSC2 (encoding tuberin).
In 1998, a consensus conference developed clinical diagnostic criteria for TSC based on specific clinical features (Table 1) (1). A diagnosis of definite TSC requires two major features or one major and two minor features. Children with probable TSC have one major plus one minor feature and a possible TSC diagnosis has either one major feature or two or more minor features. Our patient met the diagnostic requirements for definite TSC, with five major features (six hypomelanotic macules, cortical tubers, subependymal nodules, retinal hamartoma and four cardiac rhabdomyomata) and one minor feature (multiple renal cysts). Subsequent molecular genetic testing confirmed the diagnosis of TSC.
Management of TSC includes expedient diagnosis, management of neurological symptoms, genetic counselling and follow-up. Surveillance for subependymal nodules is an important part of ongoing follow-up for patients with TSC. Subependymal nodules have been noted to cause obstruction of cerebrospinal fluid flow leading to hydrocephalus, increased intracranial pressure and even death in approximately 10% of patients with TSC due to proliferative astrocytes and giant cells that protrude from the walls of the lateral and third ventricles. To date, there have been no conclusive guidelines for surveillance. The Tuberous Sclerosis Alliance suggests annual magnetic resonance imaging of the brain until 21 years of age, and then every two to three years to diagnose or monitor growth (2) .
Our patient presented with infantile spasms, one of the most common presenting features of TSC in infancy. Infants with TSC who present with infantile spasms respond particularly well to therapy with vigabatrin. Before the advent of vigabatrin, ACTH was the mainstay in the treatment of infantile spasms. Significant side effects limit the use of ACTH, making vigabatrin the drug of choice. Advantages of vigabatrin include the ability to rapidly escalate the dosage at the initiation of treatment, rapid efficacy, suitability for outpatient treatment and good tolerability. The most concerning side effect of vigabatrin is the potential for retinal toxicity, with the magnitude of the risk estimated to be 10%.
In our patient, there was resolution of infantile spasms with vigabatrin. She remained stable without any signs of neurological or cardiac compromise. She continues to be monitored for signs of retinal toxicity as well as subependymal nodule growth. She is followed by the neurology, cardiology, genetics and dermatology departments.
CLINICAL PEARLS
• The diagnosis of TSC in infancy requires a high index of suspicion. TSC should be considered in any infant presenting with seizures, particularly infantile spasms.
• Although TSC is inherited in an autosomal dominant fashion, two-thirds of cases are the result of new mutations in the TSC1 or TSC2 genes. The diagnosis of TSC in a child should prompt the investigation of TSC in first-degree relatives.
• Long-term follow-up, including monitoring of subependymal nodules, is an essential part of management.
